RecruitingNot Applicable

A Prospective Cohort Study of IRPF in China

China500 participantsStarted 2020-01-17

Plain-language summary

This is a cohort study to investigate the disease course and treatment response of patients with idiopathic retroperitoneal fibrosis（IRPF）. Methods: All the patients fulfilling diagnostic criteria of IRPF would be enrolled around China. A online database system will been established. Endpoints: The primary endpoint is to investigate the clinical manifestations of Chinese IRPF patients; the secondary endpoints including the demographic features,laboratory characteristics, immunological tests, imaging and pathological features, in addition, the treatment and prognosis of the disease.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Males and females; 18-75 years old with informed consent; Patients diagnosed with definite or possible IRPF. Exclusion Criteria: Secondary forms of IRPF; Pregnant or Females planning to bear a child recently ; Concurrent severe and/or uncontrolled and/or unstable diseases; Patients with malignancy.

What they're measuring

Organ involvements of Chinese IRPF patients

Timeframe: 5 years

Trial details

NCT IDNCT04312854

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2030-01

Contact for this trial

Yunyun Fei, MD

86-10-69158797 feiyunyun2013@hotmail.com

View on ClinicalTrials.gov More Idiopathic Retroperitoneal Fibrosis trials